Amarin mentioned positively at Roth Capital

theflyonthewall.com

Roth Capital expects Amarin's AMR101 to receive full FDA approval for the MARINE population and for the company to be bought out, or to sign a major global partnership. Share are Buy rated with a $21 price target.

Rates

View Comments (0)